ArticleNucleic acids research2026
Androgen receptor drives divergent chromatin accessibility programs in benign and malignant prostate epithelial cells.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Androgen receptor (AR) activation alters chromatin structure in prostate cancer (PC) cells, but its impact in nonmalignant prostate epithelial cells (NPEC) remains poorly characterized due to lack of representative models. We leveraged our previously established NPEC (RWPE-1-AR and RWPE-1-Ctrl) and PC (LNCaP-pcDNA3.1 and LNCaP-ARhi) cell models to profile androgen-driven chromatin responses using assay for transposase-accessible chromatin with sequencing (ATAC-seq). In the absence of androgen, NPEC and PC cells exhibited widespread differences in chromatin accessibility. Androgen stimulation amplified these differences, revealing distinct AR-mediated chromatin remodeling between the cell types. Androgen-sensitive regions were enriched for nuclear receptor binding sites (AR and glucocorticoid receptor), with AP-1 motifs more prominent in NPEC and FOXA1 motifs in PC cells. Comparison with ATAC-seq profiles obtained from clinical samples showed that NPECs resembled benign prostate hyperplasia, while PC cells mirrored untreated and castration-resistant PC, supporting the relevance of our models. Integration of ATAC-seq and mRNA-sequencing (mRNA-seq) identified model-specific AR target genes, including CDKN1C/p57 in NPEC, which may contribute to the previously observed androgen-induced growth arrest in these cells. These findings demonstrate that AR activation reprograms chromatin accessibility in normal prostate epithelium, revealing fundamental regulatory differences compared to the tumor context and underscore the importance of physiologically relevant cell models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.